Expression of target molecules in lung cancer: Challenge for a new treatment paradigm

Seminars in Oncology

Volumn 29, Issue 3 SUPPL. 9, 2002, Pages 2-8

  Hirsch, Fred R ^a   Franklin, Wilbur A ^a   Bunn Jr , Paul A ^a,b  

^a UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYCLOOXYGENASE 2 INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; GEMCITABINE; IMMUNOTOXIN; LONAFARNIB; MONOCLONAL ANTIBODY; PACLITAXEL; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; TIPIFARNIB; TRASTUZUMAB; VASCULOTROPIN;

APOPTOSIS; CANCER PATIENT; CANCER SURVIVAL; CELL PROLIFERATION; CONFERENCE PAPER; ENZYME ACTIVITY; GENE EXPRESSION REGULATION; HUMAN; LUNG CANCER; ONCOGENE NEU; PRIORITY JOURNAL; SURVIVAL RATE; T LYMPHOCYTE ACTIVATION; TARGET CELL; TISSUE SPECIFICITY;

EID: 0036317598     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/sonc.2002.34265     Document Type: Conference Paper

References (46)

1. Cancer statistics, 2001
2. Cell signaling by receptor tyrosine kinases
3. Untangling the erbB signaling network
4. The epidermal growth factor receptor: From mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia
5. The erbB signaling network: Receptor heterodimerization in development and cancer
6. Epidermal growth factor receptor (EGFR) family expression in lung cancer and premalignancy
7. Phase I studies of anti-epidermal growth factor receptor chimeric antibody alone and in combination with cisplatin
8. K1P1 and induces G1 arrest in prostate cancer cell line DU145
9. ZD1839 ('Iressa') as an anticancer agent
10. ZD 1839 (Iressa) in non-small cell lung cancer
11. A phase II trial of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor OSI-774, following platinum-based chemotherapy, in patients (pts) with advanced, EGFR-expressing, non-small cell lung cancer (NSCLC)
12. A novel approach in the treatment of cancer: Targeting the epidermal growth factor receptor
13. ZD1839 (Iressa), an EGFR-TKI, potentiates radiation/chemotherapy cytotoxicity in human non-small cell lung cancer (NSCLC) cell lines
14. HER-2 expression in malignant tumors
15. p185neu expression in human lung adenocarcinomas predicts shortened survival
16. Addition of Herceptin (humanized anti-HER2 antibody) to first-line chemotherapy for HER2 overexpressing metastatic breast cancer (HER2+/MBC) markedly increases anticancer activity. A randomized, multinational controlled phase III trial
17. Evaluation of HER2/neu expression in lung cancer tumors by immunohistochemistry and fluorescence in situ hybridization
18. Assessment of methods for tissue-based detection of the HER2/neu alteration in human breast cancer. A direct comparison of fluorescence in situ hybridization and immunohistochemistry
19. Expression of HER2/neu in human lung cancer cell lines by immunohistochemistry and fluorescence in situ hybridization and its relationship to in vitro cytotoxicity by trastuzumab and chemotherapeutic agents
20. Tumor angiogenesis: Therapeutic implications
21. Tumor angiogenesis: Past, present, and near future
22. Clinical trials of antiangiogenic drugs: Opportunities, problems, and assessment of initial results
23. Angiogenesis and non-small cell lung cancer
24. Vascular endothelial growth factor, platelet-derived endothelial growth factor and angiogenesis in non-small cell lung cancer
25. Antiangiogenic strategies and agents in clinical trials
26. A randomized phase II trial comparing rhumab VEGF (recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) plus carboplatin/paclitaxel (CP) to CP alone in patients with stage IIIB/IV NSCLC
27. SU 6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors
28. Angiostatin expression in non-small cell lung cancer
29. Development of matrix metalloproteinase inhibitors in cancer therapy
30. Final results of double-blind placebo-controlled study of adjuvant marimastat in small cell lung cancer (SCLC) patients responding to standard therapy
31. Ras oncogenes in human cancer: A review
32. Incidence and possible clinical significance of K-ras oncogene activation in adenocarcinoma of the human lung
33. A phase I trial of farnesyl transferase inhibitor SCH 66336: Evidence for biological and clinical activity
34. Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer
35. A phase I trial of the farnesyl transferase inhibitor R115777, in combination with gemcitabine and cisplatin in patients with advanced cancer
36. Anti-growth factor therapy for lung cancer
37. Prognostic significance of elevated cyclooxygenase-2 expression in primary, resected lung adenocarcinomas
38. Synergistic effects of new chemopreventive and conventional cytotoxic agents against human lung cancer cell lines
39. Retinoids suppress epidermal growth factor-induced transcription of cyclooxygenase-2 in human oral squamous carcinoma cells
40. Regulation of cyclooxygenase-2 pathway by HER2 receptor
41. Selective inhibitors of COX-2: New applications in oncology
42. Relationship between the expression of caspase-3 and the clinical outcome of patients with non-small cell lung cancer
43. Protein kinase C targeting in antineoplastic treatment strategies
44. Phase I/II trial of ISIS 3521, an antisense inhibitor of PKC-alpha, with carboplatin and paclitaxel in non-small cell lung cancer
45. Aberrant methylation of p16 (INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis
46. Translation of the biology of lung cancer to targeted therapies